I think one key factor that you need to mention is the timeline it would take to get approval for all other cancers.
Don't forget that this is a drug for THOSE IN REMISSION. I understand that you use a conservative 5%, but i think people need to realise this fact.
Just to put forward some of the what-ifs...
what treatments are we looking at? some treatments involve surgery (prostatectomy for example), which means there is no need for CVAC
Some treatments involve drugs that cut-off blood supply to the tumor, causing them to essentially die from malnourishment...this will mean that the dendritic cells will not be able toaccess the tumours, and so will be useless
It silly to get yourselves into a hype about CVACs potential in other cancers, if it isn't even proven in ovarian. lets just wait until 2015, then we will know. if it works, then it will most likely look to expand into other cancers, if it fails, well, thats millions spent on nothing
Until then, happy holding/trading.
PRR Price at posting:
14.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)